DOI QR코드

DOI QR Code

Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer

  • Wu, Min-Qing (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Hu, Pan (Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Gao, Jie (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Wei, Wei-Dong (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Xiao, Xiang-Sheng (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Tang, Hai-Lin (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Li, Xing (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Ge, Qi-Dong (Department of Breast Oncology, Sun Yat-Sen University Cancer Center) ;
  • Jia, Wei-Hua (State Key Laboratory of Oncology in South China) ;
  • Liu, Ren-Bin (Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Xie, Xiao-Ming (Department of Breast Oncology, Sun Yat-Sen University Cancer Center)
  • Published : 2013.01.31

Abstract

Background: Low tyrosine-protein phosphatase nonreceptor type 12 (PTPN12) expression may be associated with breast cancer growth, proliferation, and metastasis. However, the prognostic value of PTPN12 in breast cancer has not been clearly identified. Patients and Methods: 51 triple-negative breast cancer (TNBC) patients and 83 non-TNBC patients with a histopathology diagnosis from October 2001 to September 2006 were included in this study. Immunohistochemical staining for PTPN12 on tissue microarrays was conducted. Results: High PTPN12 expression was seen in 39.2% of TNBC and 60.2 % of non-TNBC cases. Low PTPN12 expression was associated with lymph node status (p = 0.002) and distant metastatic relapse (p = 0.002) in TNBC patients. Similarly, low PTPN12 expression in non-TNBC patients was significantly correlated with lymph node status (p = 0.002), stage (p = 0.002) and distant metastatic relapse (p = 0.039). The high PTPN12 expression group was associated with longer DFS and OS compared with low PTPN12 expression group only in TNBC cases (p = 0.005, p = 0.015), according to univariate Cox regression analysis. Conclusion: These findings provide evidence that low expression of PTPN12 is associated with worse prognosis and may be used as a potential prognostic biomarker in TNBC patients.

References

  1. Kwong A, Wong LP, Wong HN, et al (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat, 117, 683-6. https://doi.org/10.1007/s10549-009-0385-2
  2. Ma KK, Chau WW, Wong CH, et al (2012). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14. https://doi.org/10.7314/APJCP.2012.13.5.2109
  3. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74. https://doi.org/10.1158/1078-0432.CCR-04-0220
  4. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81. https://doi.org/10.1200/JCO.2007.13.1748
  5. Rhee I, Veillette A (2012). Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol, 13, 439-47. https://doi.org/10.1038/ni.2246
  6. Streit S, Ruhe JE, Knyazev P, et al (2006). PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet, 170, 48-53. https://doi.org/10.1016/j.cancergencyto.2006.05.013
  7. Sun T, Aceto N, Meerbrey KL, et al (2011). Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell, 144, 703-18. https://doi.org/10.1016/j.cell.2011.02.003
  8. Tonks NK (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol, 7, 833-46. https://doi.org/10.1038/nrm2039
  9. Villa-Moruzzi E (2011). Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst), 34, 101-12. https://doi.org/10.1155/2011/870459
  10. Westbrook TF, Hu G, Ang XL, et al (2008). SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature, 452, 370-4. https://doi.org/10.1038/nature06780
  11. Wu M, Wei W, Xiao X, et al (2012). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol, 29, 3240-9. https://doi.org/10.1007/s12032-012-0260-6
  12. Zheng Y, Yang W, Xia Y, et al (2011). Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylationdependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol, 31, 4258-69. https://doi.org/10.1128/MCB.05547-11
  13. Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol, 86, 116-9 (in German).
  14. Brady-West DC, McGrowder DA (2011). Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 12, 2139-43
  15. Cao X, Li Y, Luo RZ, et al (2012). Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg, 93, 1674-80. https://doi.org/10.1016/j.athoracsur.2011.12.056
  16. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
  17. Connolly JL (2006). Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. Arch Pathol Lab Med, 130, 287-91.
  18. Davidson D, Shi X, Zhong MC, et al (2010). The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity, 33, 167-80. https://doi.org/10.1016/j.immuni.2010.08.001
  19. DeSantis C, Siegel R, Bandi P, et al (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
  20. Espejo R, Rengifo-Cam W, Schaller MD, et al (2010). PTPPEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells. Am J Physiol Cell Physiol, 299, C454-63. https://doi.org/10.1152/ajpcell.00148.2010
  21. Friedrichs K, Gluba S, Eidtmann H, et al (1993). Overexpression of p53 and prognosis in breast cancer. Cancer, 72, 3641-7 https://doi.org/10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
  22. Galgano MT, Hampton GM, Frierson HJ (2006). Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 19, 847-53.
  23. Garton AJ, Burnham MR, Bouton AH, et al (1997) Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene, 15, 877-85. https://doi.org/10.1038/sj.onc.1201279
  24. He J, Peng R, Yuan Z, et al (2012). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29, 406-10. https://doi.org/10.1007/s12032-011-9832-0
  25. Hsu JL, Huang SY, Chow NH, et al (2003). Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem, 75, 6843-52. https://doi.org/10.1021/ac0348625
  26. Hunter T (2009) Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol, 21, 140-6. https://doi.org/10.1016/j.ceb.2009.01.028
  27. Kaplan HG, Malmgren JA, Atwood M (2009). T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J, 15, 454-60. https://doi.org/10.1111/j.1524-4741.2009.00789.x
  28. Kaplan HG, Malmgren JA (2008) Impact of triple negative phenotype on breast cancer prognosis. Breast J, 14, 456-63. https://doi.org/10.1111/j.1524-4741.2008.00622.x
  29. Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol, 37, 1217-26. https://doi.org/10.1016/j.humpath.2006.04.015
  30. Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer, 9, S73-81. https://doi.org/10.3816/CBC.2009.s.008
  31. Andersen JN, Jansen PG, Echwald SM, et al (2004). A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. Faseb J, 18, 8-30. https://doi.org/10.1096/fj.02-1212rev
  32. Angers-Loustau A, Cote JF, Charest A, et al (1999). Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration, and cytokinesis in fibroblasts. J Cell Biol, 144, 1019-31. https://doi.org/10.1083/jcb.144.5.1019

Cited by

  1. PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker vol.30, pp.3, 2013, https://doi.org/10.1007/s12032-013-0618-4
  2. The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3176-x
  3. Potential role of targeted therapies in the treatment of triple-negative breast cancer vol.27, pp.3, 2016, https://doi.org/10.1097/CAD.0000000000000328
  4. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors vol.34, pp.31, 2016, https://doi.org/10.1200/JCO.2014.59.0018
  5. Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition vol.35, pp.23, 2015, https://doi.org/10.1128/MCB.00741-15
  6. The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma vol.10, pp.3, 2018, https://doi.org/10.3390/cancers10030082
  7. Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways vol.32, pp.1, 2018, https://doi.org/10.1096/fj.201700418R
  8. The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers vol.10, pp.10, 2018, https://doi.org/10.3390/cancers10100346
  9. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer vol.24, pp.4, 2018, https://doi.org/10.1038/nm.4507